Nippon Kayaku Kabushiki Kaisha

Yamasa Shoyu Kabushiki Kaisha

Hiroshi Ohtaki

Minoru Aoki

Takashi Terada

Manami Morozumi

Minoru Nakada, Deceased

Rie Joshita

Nobuharu Fukui

Mitsuharu Shiozaki

A lanperisone hydrochloride compression-molded formulation comprising the first granules containing lanperisone hydrochloride and the second granules containing substantially no lanperisone hydrochloride but at least one pharmaceutical additive(s) selected from the group consisting of sugars, crystalline celluloses and cellulose derivatives is an excellent formulation which has a high storage stability because the decomposition of lanperisone hydrochloride is suppressed.

Lanperisone formulation

The present invention relates to hard capsules of cytarabine ocfosfate which is useful as an anti-leukemia drug applicable to oral administration. By providing the cytarabine ocfosfate hard capsule comprising (1) cytarabine ocfosfate, (2) a high molecular compound functioning as a disintegrator and (3) an alkali, there can be provided pharmaceutical preparations having excellent disintegration property and stability. The cytarabine ocfosfate hard capsules are applicable to clinical use.

Cytarabine ocfosfate hard capsule

Disclosed herein are a novel process for producing 1-.beta.-D-arabinofuranosylcytosine-5'-stearylphosphate monosodium salt, which has been expected as an oral antitumor agent, and 1-.beta.-D-arabinofranosylcytosine-5'-stearylphosphate monosodium salt monohydrate obtained from the above-mentioned monosodium salt.

Process for producing

Growing community of inventors

Yono, Japan

Hiroshi Ohtaki